Flamma SpA (“Flamma”), a preeminent Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, is proud to announce that it has completed the construction of its first cGMP Kilo Lab at its Chignolo D’Isola Headquarters in Italy.
The cGMP Kilo Lab is currently being used for an internal Flamma project in conjunction with its Flow Chemistry Pilot Unit. Meanwhile, customers with projects are reserving production slots for later in 2019.
This investment is part of the Flamma 2020 Plan to bring improvement across its network of manufacturing sites. This addition to the Chignolo site adds another option when working with Flamma’s API site.
The opening of a cGMP kilo lab not only increases capabilities of our facility but also allows our customers greater flexibility in working with Flamma. The ability to place projects in Italy or China and knowing that Flamma is actively managing all our sites is comforting to our customer base,
Corporate Development Manager
at Flamma and CEO of Flamma Innovation, remarked.
Flamma will also begin construction of its new R&D building at our headquarters in Chignolo later this year.
This will quadruple our R&D space thus allowing to continue to grow our staff of researchers to serve the pharma industry and the demands of our current customers as well as future customers. The additional benefit of this addition is the ability to have a fully dedicated analytical building for our growing quality team.
noted Kenneth Drew, Ph.D.,
Sr. Director North America Sales and Business Development.
Flamma continues to differentiate ourselves from others with our transparency and long-term vision with customers. We are proud to be family owned and run since 1950 since we do not have to answer to demands made from shareholders, private equity groups, or venture capital firms,